- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02849340
Combination of Cryosurgey and NK Immunotherapy for Recurrent Cervical Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
By enrolling patients with recurrent cervical cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using cryosurgery and natural killer (NK) cells.
The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510665
- Fuda cancer institute of Fuda cancer hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence
- Body tumor 1-6, the maximum tumor length < 5 cm
- KPS ≥ 70, lifespan > 6 months
- Platelet count ≥ 80×109/L,white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L
Exclusion Criteria:
- Patients with cardiac pacemaker
- Patients with brain metastasis
- Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cryosurgery and NK immunotherapy
In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies.
The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
|
Percutaneous ablation under CT or ultrasound guidance
Other Names:
Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
|
Active Comparator: Cryosurgery
In this group, the patients will receive comprehensive cryosurgery to clear all big tumors.
The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
|
Percutaneous ablation under CT or ultrasound guidance
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relief degree of tumors
Time Frame: 3 months
|
It will be evaluated by the Response Evaluation Criteria in Solid Tumors(RECIST)
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progress free survival(PFS)
Time Frame: 1 year
|
1 year
|
Overall survival(OS)
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NK-cervix
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Cervical Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer | Stage IIIA Cervical Cancer | Stage IIIB Cervical CancerUnited States
-
University of South AlabamaExelixisTerminatedCervical Cancer | Metastatic Cervical Cancer | Recurrent Cervical Cancer | Persistent Cervical CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Cervical Cancer | Recurrent Vaginal Cancer | Stage IB Cervical Cancer | Stage II Vaginal Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage III Vaginal Cancer | Stage IVA Cervical Cancer | Stage IVA Vaginal Cancer | Stage IVB Cervical Cancer | Stage IVB... and other conditionsUnited States
-
AkesoAkesobio Australia Pty LtdCompletedMetastatic Cervical Cancer | Recurrent Cervical CancerUnited States, Australia, New Zealand
-
BiocadUnknownCervical Cancer | Cervical Cancer Recurrent | Cervical Cancer MetastaticRussian Federation
-
Northwestern UniversityNational Cancer Institute (NCI)WithdrawnCervical Intraepithelial Neoplasia Grade 1 | Cervical Intraepithelial Neoplasia Grade 2 | Cervical Intraepithelial Neoplasia Grade 3 | Stage III Vulvar Cancer | Recurrent Cervical Cancer | Recurrent Vaginal Cancer | Recurrent Vulvar Cancer | Stage 0 Cervical Cancer | Stage 0 Vaginal Cancer | Stage 0 Vulvar... and other conditions
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Sarcoma | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Recurrent Cervical Carcinoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma | Stage I Uterine... and other conditionsUnited States
-
Sun Yat-sen UniversityCompletedRecurrent Cervical Carcinoma | Metastatic Cervical CancerChina
-
Sun Yat-sen UniversityActive, not recruitingStudy of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical CancerRecurrent Cervical CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingA Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical CancerRecurrent or Metastatic Cervical CancerChina
Clinical Trials on Cryosurgery
-
Larkin Community HospitalWithdrawn
-
Khon Kaen UniversityTerminatedHuman Papillomavirus Clearance at 12 MonthsThailand
-
Milton S. Hershey Medical CenterCompletedSeborrheic KeratosisUnited States
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedMetastatic Renal Cell CancerChina
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Completed
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedBreast Cancer RecurrentChina
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)TerminatedPain | Kidney Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer | Melanoma (Skin)United States
-
photonamic GmbH & Co. KGCompleted
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedMetastatic Esophageal CancerChina
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedNon-small Cell Lung Cancer MetastaticChina